Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: Implication in vaccine development

Vaccine

Volumn 29, Issue 5, 2011, Pages 953-959

  Sharma, Anuj ^a   Gupta, Paridhi ^a,b   Glass, Pamela J ^c   Parker, Michael D ^c   Maheshwari, Radha K ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

1,5 Iodonaphthyl azide; Inactivation; VEEV

Indexed keywords

1,5 IODONAPHTHYLAZIDE; ALUMINUM HYDROXIDE; AZIDE; FREUND ADJUVANT; INACTIVATED VACCINE; INACTIVATED VENEZUELAN EQUINE ENCEPHALITIS VIRUS VACCINE; NAPHTHYL GROUP; RNA; UNCLASSIFIED DRUG; V3000 VACCINE; V3526 VACCINE; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS INACTIVATION;

ANIMALS; AZIDES; CYTOPATHOGENIC EFFECT, VIRAL; DISEASE MODELS, ANIMAL; DISINFECTANTS; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; MICE; MICROBIAL VIABILITY; PLAQUE ASSAY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SURVIVAL ANALYSIS; VACCINES, INACTIVATED; VIRAL VACCINES; VIRULENCE; VIRUS INACTIVATION;

EID: 78751575481     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.033     Document Type: Article

References (41)

1. Weaver S.C., Ferro C., Barrera R., Boshell J., Navarro J.C. Venezuelan equine encephalitis. Annu Rev Entomol 2004, 49:141-174.
2. Steele K.E., Davis K.J., Stephan K., Kell W., Vogel P., Hart M.K. Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H/HeN and BALB/c mice. Vet Pathol 1998, 35(September (5)):386-397.
3. Koterski J., Twenhafel N., Porter A., Reed D.S., Martino-Catt S., Sobral B., et al. Gene expression profiling of nonhuman primates exposed to aerosolized Venezuelan equine encephalitis virus. FEMS Immunol Med Microbiol 2007, 51(December (3)):462-472.
4. Hawley R.J., Eitzen E.M. Biological weapons-a primer for microbiologists. Annu Rev Microbiol 2001, 55:235-253.
5. Smith D.R., Aguilar P.V., Coffey L.L., Gromowski G.D., Wang E., Weaver S.C. Venezuelan equine encephalitis virus transmission and effect on pathogenesis. Emerg Infect Dis 2006, 12(August (8)):1190-1196.
6. Weaver SC Host range, amplification and arboviral disease emergence. Arch Virol Suppl 2005, 19:33-44.
7. Ferro C., Boshell J., Moncayo A.C., Gonzalez M., Ahumada M.L., Kang W., et al. Natural enzootic vectors of Venezuelan equine encephalitis virus, Magdalena Valley, Colombia. Emerg Infect Dis 2003, 9(January (1)):49-54.
8. Bowen G.S. Experimental infection of North American mammals with epidemic Venezuelan encephalitis virus. Am J Trop Med Hyg 1976, 25(November (6)):891-899.
9. Steele K.E., Twenhafel N.A. Review Paper: Pathology of Animal Models of Alphavirus Encephalitis. Vet Pathol 2010, 47(5):790-805.
10. Paessler S., Fayzulin R.Z., Anishchenko M., Greene I.P., Weaver S.C., Frolov I. Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic. J Virol 2003, 77(September (17)):9278-9286.
11. Spertzel R.O., Crabbs C.L., Vaughn R.E. Transplacental transmission of Venezuelan equine encephalomyelitis virus in mice. Infect Immun 1972, 6(September (3)):339-343.
12. Casamassima A.C., Hess L.W., Marty A. TC-83 Venezuelan equine encephalitis vaccine exposure during pregnancy. Teratology 1987, 36(December (3)):287-289.
13. Alevizatos A.C., McKinney R.W., Feigin R.D. Live, attenuated Venezuelan equine encephalomyelitis virus vaccine. I. Clinical effects in man. Am J Trop Med Hyg 1967, 16(November (6)):762-768.
14. Pittman P.R., Makuch R.S., Mangiafico J.A., Cannon T.L., Gibbs P.H., Peters C.J. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 1996, 14(March (4)):337-343.
15. Engler R.J., Mangiafico J.A., Jahrling P., Ksiazek T.G., Pedrotti-Krueger M., Peters C.J. Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine. J Med Virol 1992, 38(December (4)):305-310.
16. Davis N.L., Brown K.W., Greenwald G.F., Zajac A.J., Zacny V.L., Smith J.F., et al. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology 1995, 212(September (1)):102-110.
17. Rao V., Hinz M.E., Roberts B.A., Fine D. Environmental hazard assessment of Venezuelan equine encephalitis virus vaccine candidate strain V3526. Vaccine 2004, 22(June (20)):2667-2673.
18. Rao V., Hinz M.E., Roberts B.A., Fine D. Toxicity assessment of Venezuelan Equine Encephalitis virus vaccine candidate strain V3526. Vaccine 2006, 24(March (10)):1710-1715.
19. Fine D.L., Jenkins E., Martin S.S., Glass P., Parker M.D., Grimm B A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV). J Virol Methods 2009, (November).
20. Hart M.K., Caswell-Stephan K., Bakken R., Tammariello R., Pratt W., Davis N., et al. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine 2000, 18(July (26)):3067-3075.
21. Pratt W.D., Davis N.L., Johnston R.E., Smith J.F. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 2003, 21(September (25-26)):3854-3862.
22. Reed D.S., Lind C.M., Lackemeyer M.G., Sullivan L.J., Pratt W.D., Parker M.D. Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus. Vaccine 2005, 23(May (24)):3139-3147.
23. Fine D.L., Roberts B.A., Terpening S.J., Mott J., Vasconcelos D., House R.V. Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates. Vaccine 2008, 26(June (27-28)):3497-3506.
24. Martin S.S., Bakken R.R., Lind C.M., Reed D.S., Price J.L., Koeller C.A., et al. Telemetric analysis to detect febrile responses in mice following vaccination with a live-attenuated virus vaccine. Vaccine 2009, 27(November (49)):6814-6823.
25. Holley P., Fine D.L., Terpening S.J., Mallory C.J., Main C.A., Snow D.M., et al. Safety of an attenuated Venezuelan equine encephalitis virus (VEEV) vaccine in humans 2008.
26. Sharma A., Raviv Y., Puri A., Viard M., Blumenthal R., Maheshwari R.K. Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide. Biochem Biophys Res Commun 2007, 358(June (2)):392-398.
27. Kahane I., Gitler C. Red cell membrane glycophorin labeling from within the lipid bilayer. Science 1978, 201(July (4353)):351-352.
28. Raviv Y., Salomon Y., Gitler C., Bercovici T. Selective labeling of proteins in biological systems by photosensitization of 5-iodonaphthalene-1-azide. Proc Natl Acad Sci U S A 1987, 84(September (17)):6103-6107.
29. Bercovici T., Gitler C. 5-[125I]Iodonaphthyl azide, a reagent to determine the penetration of proteins into the lipid bilayer of biological membranes. Biochemistry 1978, 17(April (8)):1484-1489.
30. Raviv Y., Bercovici T., Gitler C., Salomon Y. Selective photoinduced uncoupling of the response of adenylate cyclase to gonadotropins by 5-iodonaphthyl 1-azide. Biochemistry 1984, 23(January (3)):503-508.
31. Raviv Y., Viard M., Bess J.W., Chertova E., Blumenthal R. Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. J Virol 2005, 79(October (19)):12394-12400.
32. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., Viard M., Aitichou M., et al. Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J Infect Dis 2007, 196(November (Suppl. 2)):S276-S283.
33. Raviv Y., Blumenthal R., Tompkins S.M., Humberd J., Hogan R.J., Viard M. Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. J Virol 2008, 82(May (9)):4612-4619.
34. Turell M.J., Parker M.D. Protection of hamsters by Venezuelan equine encephalitis virus candidate vaccine V3526 against lethal challenge by mosquito bite and intraperitoneal injection. Am J Trop Med Hyg 2008, 78(February (2)):328-332.
35. Sharma A., Maheshwari R.K. Oligonucleotide array analysis of Toll-like receptors and associated signalling genes in Venezuelan equine encephalitis virus-infected mouse brain. J Gen Virol 2009, 90(August (Pt 8)):1836-1847.
36. Overman J.R. Antibody response of suckling mice to mumps virus. I. Immune response following immunization with mumps virus vaccine. J Immunol 1954, 73(October (4)):244-248.
37. Griffin D.E., Levine B., Tyor W.R., Tucker P.C., Hardwick J.M. Age-dependent susceptibility to fatal encephalitis: alphavirus infection of neurons. Arch Virol Suppl 1994, 9:31-39.
38. Pushko P., Bray M., Ludwig G.V., Parker M., Schmaljohn A., Sanchez A., et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000, 19(August (1)):142-153.
39. Hernandez R., Sinodis C., Brown D.T. Sindbis virus: propagation, quantification, and storage. Curr Protoc Microbiol 2005, (October). Chapter 15:Unit 15B 1.
40. Viard M., Ablan S.D., Zhou M., Veenstra T.D., Freed E.O., Raviv Y., et al. Photoinduced reactivity of the HIV-1 envelope glycoprotein with a membrane-embedded probe reveals insertion of portions of the HIV-1 Gp41 cytoplasmic tail into the viral membrane. Biochemistry 2008, 47(February (7)):1977-1983.
41. Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, et al. Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB. Vaccine 2010;28(January (4)):1031-40.